John Achermann
London, United Kingdom
Thu 10 11:30
S17
Symposium 1 – Update on Adrenal Disorders
Recent advances in our understanding of adrenal disease and development
London, United Kingdom
Professor Adrian Clark
London, UK
Thu 10 11:00
S16
Symposium 1 – Update on Adrenal Disorders
Familial Glucocorticoid Deficiency: An Update
London, UK
Leo Dunkel
London, UK
Thu 10 16:00
S20
Symposium 2 – Pubertal Disorders
Management of Delayed Puberty
London, UK
Roman Havorka
Fri 11 15:15
S26
Symposium 4 – Insulin Resistance and Type 2 Diabetes: Novel Insights
Update on closed loop systems for the treatment of Type 1 DM
Rury Holman
Fri 11 09:30
S22
Symposium 3 – Novel therapies/management in Diabetes Mellitus
Use of insulin for the early treatment of Type 2 Diabetes Mellitus
Peter Jones
Fri 11 14:15
S24
Symposium 4 – Insulin Resistance and Type 2 Diabetes: Novel Insights
Islet cell transplantation: an update
Nils Krone
Sheffield, UK
Thu 10 12:00
S18
Symposium 1 – Update on Adrenal Disorders
Health problems in Congenital Adrenal Hyperplasia – a UK perspective
Sheffield, UK
Mark Peakman
Fri 11 14:45
S25
Symposium 4 – Insulin Resistance and Type 2 Diabetes: Novel Insights
Immunology of Type 1 Diabetes Mellitus
Nelly Pitteloud
Lausanne, Switzerland
Thu 10 15:30
S19
Symposium 2 – Pubertal Disorders
Novel insights into Hypogonadotrophic Hypogonadism
Lausanne, Switzerland
Robert Semple
Edinburgh, UK
Fri 11 09:00
S21
Symposium 3 – Novel therapies/management in Diabetes Mellitus
Insulin resistance syndromes
Edinburgh, UK
Wed 09 16:00
Main Meeting Registration
Wed 09 17:30
Sanofi-Aventis Satellite Symposium
Satellite Symposium Programme (pdf)(1.18mb)”
Wed 09 19:00
Welcome Reception
Wed 09 19:45
Speakers Dinner by invitation only
Novo Nordisk
Thu 10 08:50
Welcome
Chair: Mehul Dattani
Thu 10 09:00
OC1.1
Oral Communications 1
Surgical treatment of children with hyperparathyroidism: single centre experience
Thu 10 09:11
OC1.2
Oral Communications 1
Isolation and characterisation of tumorigenic progenitors/stem cells with a stabilizing mutation in beta-catenin, in a mouse model of human adamantinomatous craniopharyngioma.
Thu 10 09:22
OC1.3
Oral Communications 1
High likelihood of malignancy in patients presenting with a thyroid nodule
Thu 10 09:33
OC1.4
Oral Communications 1
Growth Retardation and Severe Constipation due to the first human, dominant negative Thyroid Hormone Receptor Alpha mutation
Thu 10 09:44
OC1.5
Oral Communications 1
DECONVOLUTION ANALYSIS OF 24H SERUM CORTISOL PROFILES INFORMS THE AMOUNT AND DISTRIBUTION OF HYDROCORTSIONE REPLACEMENT THERAPY
Thu 10 09:55
OC1.6
Oral Communications 1
Twenty novel mutations in nicotinamide nucleotide transhydrogenase (NNT) causing FGD
Thu 10 10:06
OC1.7
Oral Communications 1
Mild GH deficiency due to two novel homozygous mutations in the gene encoding Growth-Hormone Releasing Hormone receptor (GHRHR) in a single family
Thu 10 10:17
OC1.8
Oral Communications 1
Mutations in PROKR2 but not PROK2 are associated with congenital hypopituitarism and septo-optic dysplasia
Thu 10 10:30
Coffee
Thu 10 11:00
S16
Symposium 1 – Update on Adrenal Disorders
Familial Glucocorticoid Deficiency: An Update
London, UK
Thu 10 11:30
S17
Symposium 1 – Update on Adrenal Disorders
Recent advances in our understanding of adrenal disease and development
London, United Kingdom
Thu 10 12:00
S18
Symposium 1 – Update on Adrenal Disorders
Health problems in Congenital Adrenal Hyperplasia – a UK perspective
Sheffield, UK
Thu 10 12:30
Lunch
Thu 10 13:15
Poster Tour
Thu 10 14:00
OC2.1
Oral Communications 2 - Brief Communications
Sperm cryopreservation in adolescent minors with cancer: factors predicting pre-treatment semen quality in 79 minors aged 12-18 years over 10 years
Thu 10 14:06
OC2.2
Oral Communications 2 - Brief Communications
The assessment of bone microarchitecture by high resolution magnetic resonance imaging (micro MRI) in young adults with childhood onset disease
Thu 10 14:12
OC2.3
Oral Communications 2 - Brief Communications
MCM4 mutation causes a novel DNA replication disorder associated with short stature and adrenal failure
Thu 10 14:18
OC2.4
Oral Communications 2 - Brief Communications
Short Term Effects of Recombinant IGF-I therapy in children with Laron’s Syndrome.
Thu 10 14:24
OC2.5
Oral Communications 2 - Brief Communications
A selective effect of IGFBP-3 on brain volumes in healthy children
Thu 10 14:30
OC2.6
Oral Communications 2 - Brief Communications
What defines Vitamin D deficiency biochemically in children?
Thu 10 14:36
OC2.7
Oral Communications 2 - Brief Communications
Selective reduction in trabecular bone mineral density during treatment for childhood acute lymphoblastic leukaemia
Thu 10 14:42
OC2.8
Oral Communications 2 - Brief Communications
Novel SOX2 mutation: from clinical phenotype to identification of new molecular mechanisms of SOX2 action and interactions.
Thu 10 15:00
Tea
Thu 10 15:30
S19
Symposium 2 – Pubertal Disorders
Novel insights into Hypogonadotrophic Hypogonadism
Lausanne, Switzerland
Thu 10 16:00
S20
Symposium 2 – Pubertal Disorders
Management of Delayed Puberty
London, UK
Thu 10 16:45
BSPED Annual General Meeting
Thu 10 19:45
Pre-dinner Welcome Reception
Thu 10 20:15
Conference Dinner
Fri 11 09:00
S21
Symposium 3 – Novel therapies/management in Diabetes Mellitus
Insulin resistance syndromes
Edinburgh, UK
Fri 11 09:30
S22
Symposium 3 – Novel therapies/management in Diabetes Mellitus
Use of insulin for the early treatment of Type 2 Diabetes Mellitus
Fri 11 10:00
BSPED Research Award winners presentation from 2010
Tim Cheetham
Fri 11 10:20
BSPED Website Launch
Justin Davies
Fri 11 10:30
Coffee
Fri 11 11:00
Plenary Guest Lecture: Advances in our understanding of the Genetic Causes of Obesity
Sadaaf Farooqi
Fri 11 11:45
OC3.1
Oral Communications 3 - Brief Communications
The impact of growth hormone deficiency (GHD) and growth hormone treatment (GHTx) on the cardiovascular risk in survivors of bone marrow transplantation with total body irradiation (BMT/TBI) in childhood
Fri 11 11:56
OC3.2
Oral Communications 3 - Brief Communications
Clinical, genetic, histological and radiological heterogeneity of focal forms of congenital hyperinsulinism
Fri 11 12:07
OC3.3
Oral Communications 3 - Brief Communications
Laparoscopic near total pancreatectomy for medically unresponsive diffuse congenital hyperinsulinism
Fri 11 12:18
OC3.4
Oral Communications 3 - Brief Communications
The heterogeneity of hyperinsulinaemic hypoglycaemia in 19 patients with Beckwith-Wiedemann syndrome due to KvDMR1 hypomethylation.
Fri 11 12:30
Lunch
Fri 11 13:30
OC4.1
Oral Communications 4 - Brief Communications
Ethnicity Rather Than Deprivation Impacts on Diabetes Control and use of Treatment Regimen
Fri 11 13:41
OC4.2
Oral Communications 4 - Brief Communications
White UK children are older, more obese and more insulin resistant than non-White UK children at diagnosis of type 2 diabetes: baseline results of the UK national Type 2 diabetes cohort.
Fri 11 13:52
OC4.3
Oral Communications 4 - Brief Communications
Non-linear Dynamic Analysis of Glucose Regulation in Subjects with Type 2 Diabetes and Controls - Observed Variability and Liability (OVAL)
Fri 11 14:03
OC4.4
Oral Communications 4 - Brief Communications
Natural history of background retinopathy in children and young people with diabetes
Fri 11 14:15
S24
Symposium 4 – Insulin Resistance and Type 2 Diabetes: Novel Insights
Islet cell transplantation: an update
Fri 11 14:45
S25
Symposium 4 – Insulin Resistance and Type 2 Diabetes: Novel Insights
Immunology of Type 1 Diabetes Mellitus
Fri 11 15:15
S26
Symposium 4 – Insulin Resistance and Type 2 Diabetes: Novel Insights
Update on closed loop systems for the treatment of Type 1 DM
Fri 11 15:55
Close of Meeting

0 result(s) found.